Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.

Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Pomalidomide Chemical Structure

Pomalidomide Chemical Structure
Molecular Weight: 273.24

Validation & Quality Control

Customer Product Validation(2)

Quality Control & MSDS

Related Compound Libraries

Pomalidomide is available in the following compound libraries:

TNF-alpha Inhibitors with Unique Features

  • Most Potent TNF-alpha Inhibitor

    QNZ (EVP4593) TNF-α production, IC50=7 nM.

  • FDA-approved TNF-alpha Inhibitor

    Lenalidomide (CC-5013) Approved by FDA for myelodysplastic syndromes (MDS).

  • Newest TNF-alpha Inhibitor

    Necrostatin-1 Specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM.

  • Classic TNF-alpha Inhibitor

    Thalidomide A sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers.

Product Information

  • Compare TNF-alpha Inhibitors
    Compare TNF-alpha Products
  • Research Area

Product Description

Biological Activity

Description Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.
Targets TNF-α [1]
IC50 13 nM
In vitro Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. [1] Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. [2] Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels. Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. [3] Exposure of Raji cells to various concentrations of Pomalidomide (2.5-40 μg/mL) for 48 hours leads to a significant decrease in cell proliferation and DNA synthesis. There is a reduction of ~40% compared to vehicle-treated controls. [4]
In vivo Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. Administration of Pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of CC5013/rituximab treatment and 45 days of rituximab nonotherapy. The synergistic effect of Pomalidomide and rituximab can be completely abrogated by depletion of NK cells, supporting the proposal that NK cell expansion is one mechanism by which Pomalidomide may augment rituximab antitumor activity. [4]
Features A derivative of thalidomide and up to 10,000 times more potent than thalidomide.

Protocol(Only for Reference)

Kinase Assay: [1]

Inhibition of TNF-α synthesis TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that inhibits TNF- production by 50% (IC50) is calculated by nonlinear regression analysis. The human whole blood TNF- inhibition assay is run in a similar fashion to the PBMC assay except that heparinized fresh human whole blood is plated directly into microtiter plates.

Cell Assay: [4]

Cell lines Raji, SU-DHL-4 and SU-DHL-10 cell lines
Concentrations Dissolved in DMSO, final concentrations 2.5-40 μg/mL
Incubation Time 24 or 48 hours
Method For assessment of cell apoptosis, Lymphoma cell lines are exposed to Pomalidomide (5 μg/mL) for 24 hours or 48 hours. The cells are stained with FITC-labeled Annexin V and propidium iodine. Cell apoptosis is analyzed by multicolor flow cytometric analysis using a fluorescence-activated cell sorter/FACStar Plus flow cytometer. Cells are scored as apoptotic if they are Annexin V–positive and propidium iodine–negative/positive (early and late apoptosis, respectively). For determination of cell proliferation, the Lymphoma cell lines are exposed to Pomalidomide (2.5, 5, 10, 20, and 40 μg/mL) for 24 hours or 48 hours. 1 μCi per well (96-well plate) of [3H]-thymidine is added and cells are incubated for another 18 hours. Cells are then harvested using the Harvest system into the 96-well glass filters and [3H]-thymidine uptake is measured using an automated scintillation counter.

Animal Study: [4]

Animal Models Disseminated lymphoma-bearing SCID mice
Formulation Dissolved in DMSO to make a 10 mg/mL stock solution and diluted to a final concentration of 1 mg/mL in sterile 0.9% normal saline.
Dosages 0.5 mg/kg
Administration Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] Muller GW, et al. Bioorg Med Chem Lett, 1999, 9(11), 1625-1630.

[2] Galustian C, et al. Cancer Immunol Immunother, 2009, 58(7), 1033-1045.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2015-08-29)

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT02343042 Not yet recruiting Multiple Myeloma Karyopharm Therapeutics, Inc September 2015 Phase 1|Phase 2
NCT02415153 Recruiting Recurrent Central Nervous System Neoplasm|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervou  ...more Recurrent Central Nervous System Neoplasm|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) July 2015 Phase 1
NCT02283775 Recruiting Haematological Malignancy Sanofi May 2015 Phase 1
NCT02384083 Not yet recruiting Multiple Myeloma PETHEMA Foundation|Array BioPharma|Celgene Corporation April 2015 Phase 1|Phase 2
NCT02400242 Recruiting Multiple Myeloma Acetylon Pharmaceuticals Incorporated April 2015 Phase 1

view more

Chemical Information

Download Pomalidomide SDF
Molecular Weight (MW) 273.24


CAS No. 19171-19-8
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms CC-4047
Solubility (25°C) * In vitro DMSO 55 mg/mL (201.28 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80 15 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

Customer Product Validation (2)

Click to enlarge
Source Blood 2011 118, 4771-4779. Pomalidomide purchased from Selleck
Method MTT assay
Cell Lines OPM2 cells
Concentrations 0-1000 nM
Incubation Time 3 d
Results OPM2 was subsequently tested with other anti-myeloma drugs, showing resistance to lenalidomide and pomalidomide.

Click to enlarge
Source Cancer Immunol Immunother 2014 63(10), 1023-36. Pomalidomide purchased from Selleck
Method Flow cytometry
Cell Lines CD8+ T cells
Concentrations 0.5 uM
Incubation Time 48 h
Results The number of tetramer+ cells was even reduced upon stimulation in the presence of pomalidomide (c). Lenalidomide and pomalidomide had differential effects on the frequency of antigen-specific (4-1BB+) CTLs (CD107a+ CD8+ T cells) and cytokine-producing (IFN-γ+, TNF-α+, IL-2+ and/or MIP-1β+) CD8+ T cells, which were increased in the lenalidomide, but decreased in the pomalidomide conditions.

Product Use Citation (9)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related TNF-alpha Products

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • BV-6

    BV-6 is a SMAC mimetic, dual cIAP and XIAP inhibitor.

  • LCL161

    LCL161, a SMAC mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP). Phase 2.

  • Lenalidomide (CC-5013)

    Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs.

  • Thalidomide

    Thalidomide was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. Thalidomide inhibits an E3 ubiquitin ligase, which is a CRBN-DDB1-Cul4A complex.

  • Necrostatin-1

    Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells.

    Features:A powerful tool for characterizing the role of necroptosis with characterized primary target.


    Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

    Features:A key compound for apoptosis studies.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • ABT-737

    ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Recently Viewed Items

Tags: buy Pomalidomide | Pomalidomide ic50 | Pomalidomide price | Pomalidomide cost | Pomalidomide solubility dmso | Pomalidomide purchase | Pomalidomide manufacturer | Pomalidomide research buy | Pomalidomide order | Pomalidomide mouse | Pomalidomide chemical structure | Pomalidomide mw | Pomalidomide molecular weight | Pomalidomide datasheet | Pomalidomide supplier | Pomalidomide in vitro | Pomalidomide cell line | Pomalidomide concentration | Pomalidomide nmr
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
Contact Us